Ironwood Pharmaceuticals to Present New Linaclotide Data and Unveil Findings From GI Disease Surveys at Digestive Disease Week 2021
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today announced that the company and its collaborators will present seven posters – four of which have been named posters of distinction – during the Digestive Disease Week (DDW) 2021 virtual meeting being held from May 21 through May 23, 2021.
Two posters of distinction will discuss the impact of linaclotide on visceral hypersensitivity. Ironwood is focused on advancing the science and understanding of visceral hypersensitivity, which is one of the main underlying causes of irritable bowel syndrome with constipation (IBS-C).1 Other data will highlight disease burden and care-seeking behavior among patients with IBS-C during the COVID-19 pandemic, and additional posters will reveal findings from a nationwide GI disease survey of nearly 90,000 Americans.
“Ironwood is committed to expanding our understanding of the pathology, prevalence and real-world impact of IBS and other GI diseases among varied populations and to sharing those learnings with the medical community with the goal of advancing care for patients,” said Mike Shetzline, M.D., Ph.D., chief medical officer, senior vice president and head of drug development at Ironwood. “We look forward to the upcoming DDW meeting to discuss the important insights from our clinical and basic research.”
Results from a Nationwide Survey of Nearly 90,000 Americans, by Christopher Almario, M.D., MSHPM, Cedars-Sinai Medical Center, Los Angeles, CA
- Prevalence of Bowel Disorders in Multiple Sclerosis and Parkinson’s Disease (poster of distinction; presentation number Fr080) will be presented on Friday, May 21, 12:15 p.m. to 1:00 p.m.
- Prevalence and Burden of Illness of Rome IV Chronic Idiopathic Constipation, Opioid-Induced Constipation, and Opioid-Exacerbated Constipation in the U.S. (presentation number Fr438) will be presented on Friday, May 21, 12:15 p.m. to 1:00 p.m.
- Prevalence and Burden of Illness of Rome IV Irritable Bowel Syndrome in the U.S. (poster of distinction; presentation number Su085) will be presented on Sunday, May 23, 12:15 p.m. to 1:00 p.m.
IBS-C Disease Burden During COVID-19